Indivior PLC (NASDAQ:INDV) Stock Rated “Buy” by Sell-Side Analysts

Shares of Indivior PLC (NASDAQ:INDV – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $46.40.

INDV has been the topic of a number of recent research reports. Craig Hallum reaffirmed a “buy” rating and set a $53.00 price target on shares of Indivior in a research report on Tuesday, August 4th. Wall Street Zen lowered shares of Indivior from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 31st. Barclays raised their target price on shares of Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd.

Read Our Latest Analysis on Indivior

Insider Activity at Indivior

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was purchased at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in INDV. Intech Investment Management LLC raised its holdings in Indivior by 0.4% during the third quarter. Intech Investment Management LLC now owns 108,262 shares of the company’s stock worth $3,881,000 after purchasing an additional 444 shares in the last quarter. Illinois Municipal Retirement Fund boosted its stake in Indivior by 1.0% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 62,933 shares of the company’s stock valued at $2,256,000 after purchasing an additional 611 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after purchasing an additional 1,076 shares in the last quarter. Virtus Advisers LLC increased its position in shares of Indivior by 24.9% during the 3rd quarter. Virtus Advisers LLC now owns 7,871 shares of the company’s stock valued at $282,000 after purchasing an additional 1,570 shares during the period. Finally, TD Waterhouse Canada Inc. acquired a new position in shares of Indivior during the 2nd quarter valued at $63,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Stock Up 0.2%

Shares of NASDAQ INDV opened at $28.21 on Monday. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84. Indivior has a 52 week low of $27.68 and a 52 week high of $42.81. The firm has a 50-day moving average price of $34.24 and a 200 day moving average price of $35.48.

Indivior (NASDAQ:INDV – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.26. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. The company had revenue of $356.00 million during the quarter, compared to analysts’ expectations of $329.35 million. Equities research analysts expect that Indivior will post 3.66 EPS for the current fiscal year.

Indivior Dividend Announcement

The business also recently disclosed a special dividend, which was paid on Friday, November 6th. Shareholders of record on Friday, October 30th were given a $8.13 dividend. The ex-dividend date of this dividend was Tuesday, November 3rd.

Indivior Company Profile

(Get Free Report)

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.

Further Reading

Analyst Recommendations for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.